Bristol-Myers Falls Most in 14 Years as Drug Misses Goal: ChartBy
Bristol-Myers Squibb Co. slumped as much as 18 percent, the most in 14 years, after saying that the use of its drug Opdivo as a single agent for lung cancer failed in a pivotal trial. Shares of Merck & Co., the maker of Opdivo competitor Keytruda, jumped as much as 8.2 percent, the most since 2009.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.